Sodium Selenite Se 75

Publisher Website
Google Scholar
Abstract
Brain scanning, with any of several radioactive pharmaceutical agents, permits the accurate localization of intracranial lesions. Bone scanning, with radioactive strontium, allows the detection of localized disease of the skeleton. However, none of the agents in current use is specific for tumors. In an attempt to improve the diagnostic accuracy of radioisotope scanning, the usefulness of a new agent, selenite Se 75, has been studied in patients with intracranial disease and in cases of localized lesions of bone. Compared with conventional brain-scanning agents, selenite was equally effective in detecting intracranial tumors and yielded fewer abnormal scans in cases of cerebrovascular disease. In the patients with bone lesions, localization of selenite occurred in tumors and uniformly normal scans were obtained in nonneoplastic disease. Because of its relative specificity for tumors, selenite is of value, particularly when used in combination with conventional scanning agents, in the diagnosis of tumors of brain and bone.

This publication has 0 references indexed in Scilit: